These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 19877181)

  • 1. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety.
    Vitale A; Volk ML; Pastorelli D; Lonardi S; Farinati F; Burra P; Angeli P; Cillo U
    Hepatology; 2010 Jan; 51(1):165-73. PubMed ID: 19877181
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic evaluation of sorafenib in unresectable hepatocellular carcinoma.
    Carr BI; Carroll S; Muszbek N; Gondek K
    J Gastroenterol Hepatol; 2010 Nov; 25(11):1739-46. PubMed ID: 21039835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma.
    Cammà C; Cabibbo G; Petta S; Enea M; Iavarone M; Grieco A; Gasbarrini A; Villa E; Zavaglia C; Bruno R; Colombo M; Craxì A; ;
    Hepatology; 2013 Mar; 57(3):1046-54. PubMed ID: 23299720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Utility-based criteria for selecting patients with hepatocellular carcinoma for liver transplantation: A multicenter cohort study using the alpha-fetoprotein model as a survival predictor.
    Vitale A; Farinati F; Burra P; Trevisani F; Giannini EG; Ciccarese F; Piscaglia F; Rapaccini GL; Di Marco M; Caturelli E; Zoli M; Borzio F; Cabibbo G; Felder M; Sacco R; Morisco F; Missale G; Foschi FG; Gasbarrini A; Svegliati Baroni G; Virdone R; Chiaramonte M; Spolverato G; Cillo U;
    Liver Transpl; 2015 Oct; 21(10):1250-8. PubMed ID: 26183802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma.
    Spolverato G; Vitale A; Ejaz A; Kim Y; Maithel SK; Cosgrove DP; Pawlik TM
    World J Surg; 2015 Jun; 39(6):1474-84. PubMed ID: 25665675
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis.
    Wörns MA; Weinmann A; Pfingst K; Schulte-Sasse C; Messow CM; Schulze-Bergkamen H; Teufel A; Schuchmann M; Kanzler S; Düber C; Otto G; Galle PR
    J Clin Gastroenterol; 2009; 43(5):489-95. PubMed ID: 19247201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib for the treatment of advanced hepatocellular carcinoma.
    Connock M; Round J; Bayliss S; Tubeuf S; Greenheld W; Moore D
    Health Technol Assess; 2010 May; 14 Suppl 1():17-21. PubMed ID: 20507799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.
    Hollebecque A; Cattan S; Romano O; Sergent G; Mourad A; Louvet A; Dharancy S; Boleslawski E; Truant S; Pruvot FR; Hebbar M; Ernst O; Mathurin P
    Aliment Pharmacol Ther; 2011 Nov; 34(10):1193-201. PubMed ID: 21958438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant.
    Truesdale AE; Caldwell SH; Shah NL; Argo CK; Al-Osaimi AM; Schmitt TM; Northup PG
    Transpl Int; 2011 Oct; 24(10):991-8. PubMed ID: 21777298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis.
    Pinter M; Sieghart W; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Plank C; Peck-Radosavljevic M
    Oncologist; 2009 Jan; 14(1):70-6. PubMed ID: 19144684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
    Saab S; McTigue M; Finn RS; Busuttil RW
    Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of patients with advanced hepatocellular carcinoma: sorafenib versus other treatments.
    Kim HY; Park JW; Nam BH; Kim HK; Choi JI; Kim TH; Kim HB; Kim CM
    J Gastroenterol Hepatol; 2011 Nov; 26(11):1612-8. PubMed ID: 21517968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
    Sposito C; Mariani L; Germini A; Flores Reyes M; Bongini M; Grossi G; Bhoori S; Mazzaferro V
    J Hepatol; 2013 Jul; 59(1):59-66. PubMed ID: 23500153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation?
    Vitale A; Boccagni P; Kertusha X; Zanus G; D'Amico F; Lodo E; Pastorelli D; Ramirez Morales R; Lombardi G; Senzolo M; Burra P; Cillo U
    Transplant Proc; 2012 Sep; 44(7):1989-91. PubMed ID: 22974889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
    Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
    Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
    Weinmann A; Niederle IM; Koch S; Hoppe-Lotichius M; Heise M; Düber C; Schuchmann M; Otto G; Galle PR; Wörns MA
    Dig Liver Dis; 2012 May; 44(5):432-7. PubMed ID: 22265328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver transplantation in a patient treated by sorafenib for hepatocellular carcinoma.
    Borentain P; Gregoire E; Hardwigsen J; Garcia S; Durieux O; Le Treut YP; Gérolami R
    Clin Res Hepatol Gastroenterol; 2011 Mar; 35(3):234-6. PubMed ID: 21345761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib for recurrent hepatocellular carcinoma after liver transplantation.
    Yoon DH; Ryoo BY; Ryu MH; Lee SG; Hwang S; Suh DJ; Lee HC; Kim TW; Ahn CS; Kim KH; Moon DB; Kang YK
    Jpn J Clin Oncol; 2010 Aug; 40(8):768-73. PubMed ID: 20494947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Pinter M; Sieghart W; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Matejka J; Stauber R; Buder R; Grünberger B; Schöniger-Hekele M; Müller C; Peck-Radosavljevic M
    Aliment Pharmacol Ther; 2011 Oct; 34(8):949-59. PubMed ID: 21883324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib improves the survival of patients with advanced hepatocellular carcinoma: a meta-analysis of randomized trials.
    Zhang T; Ding X; Wei D; Cheng P; Su X; Liu H; Wang D; Gao H
    Anticancer Drugs; 2010 Mar; 21(3):326-32. PubMed ID: 20016366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.